# Best Performing European Stocks 2026: Top 10 Winners from STOXX, DAX, and FTSE
Europe's stock markets have been a tale of two speeds in 2026. While continental Europe lagged the US, certain European stocks have thrived, driven by industrial strength, AI infrastructure, and defensive positioning. From German automation to Swiss pharma to Dutch semiconductors, European winners tell a story of quality, diversification, and resilience. If you're investing in European equities whether through ETFs or individual picks understanding which stocks have outperformed is crucial for portfolio construction. Let's break down the 10 best-performing European stocks of 2026 and what's driving their gains. (For the other side of the ledger, see our analysis of the [10 worst-performing European stocks of 2026](#worst-performers).)
The Winners: Automation, AI Infrastructure, Luxury, and Pharma
Europe's stock market winners reflect the continent's competitive advantages: industrial engineering, high-end manufacturing, and pharmaceutical innovation. Unlike the US market dominated by mega-cap tech, European winners are more diverse.
1. ASML Holding (ASML) Up 92%+
ASML is the world's leading supplier of semiconductor manufacturing equipment (lithography machines). The company's extreme ultraviolet (EUV) technology is essential for making cutting-edge chips. As global capex on chip fabs surged in 2026 (Intel, Samsung, TSMC all expanding), ASML saw orders explode. Gross margins are 50%+. The company is supply-constrained, not demand-constrained. Valuation is premium at 35-40x earnings, but justified by secular AI-driven chip demand. Risk: China export restrictions; customer inventory corrections.
2. Siemens (SIE) Up 68%+
Siemens is a German industrial conglomerate with exposure to automation, electrification, and digitalization. The company's factory automation business (Siemens Digital Industries) is booming as manufacturers adopt AI and robotics. Software revenue is growing 20%+ and carries higher margins. The stock was cheap at 18x earnings; now at 22x, it's reasonably valued for 8-10% growth. Dividend yield is 3.5%+ and growing. Risk: cyclical exposure if manufacturing slows; geopolitical tension affecting China sales.
3. SAP SE (SAP) Up 75%+
SAP is Europe's largest software company and a global player in enterprise resource planning (ERP). The company has successfully pivoted to cloud (SAP Cloud ERP) and AI (Joule, their generative AI assistant for business). Cloud revenue is growing 25%+, offsetting legacy on-premise decline. Gross margins are expanding. Valuation at 28-30x earnings is reasonable for a 12-15% grower with sticky enterprise customers. Risk: slower enterprise AI adoption; competitive pressure from Salesforce, Oracle.
4. Novo Nordisk (NVO) Up 56%+
Novo Nordisk is a Danish pharma giant riding the GLP-1 drug wave. Ozempic (for diabetes) and Wegovy (for weight loss) have become blockbuster drugs, with Ozempic alone generating $13B+ in annual revenue. Obesity is a $200B+ global market. The company is expanding manufacturing to meet demand. Valuation is 30-35x earnings, which reflects growth but also peak-GLP-1 risk. Margins are 60%+. Risk: competition from Eli Lilly (Mounjaro) and oral GLP-1s; pricing pressure from governments.
5. LVMH Moët Hennessy (MC) Up 48%+
LVMH is the world's largest luxury goods conglomerate (Louis Vuitton, Dior, Fendi, Celine). Luxury spending has recovered in 2026 as wealthy consumers continue to splurge. The company's diversified brand portfolio (200+ brands) provides stability. Operating margins are 20%+. China sales are recovering after 2024-2025 weakness. Valuation at 20-22x earnings is reasonable for a 5-7% grower with pricing power. Risk: Chinese luxury demand slowing again; trade war escalation; brand perception issues.
6. Roche Holding (RHHBY) Up 42%+
Roche is a Swiss pharma giant with blockbuster drugs (Herceptin, Avastin) and diagnostics. The company is pivoting to personalized medicine and oncology, where margins are highest. Gross margins are 85%+ (drug patents provide moat). Valuation at 25-28x earnings reflects mature growth (3-5% annually) with defensive appeal. Dividend yield is 2.8%+ and growing. Risk: drug patent expirations; regulatory pressure on drug pricing; R&D pipeline disappointments.
7. TotalEnergies (TTEF) Up 52%+
TotalEnergies is a French energy giant with both traditional oil/gas and renewable energy exposure. The company has invested heavily in solar, wind, and battery storage. Energy transition capex is being deployed at scale. Dividend yield is 5.5%+ and well-supported. Valuation at 9-10x earnings reflects commodity exposure but also energy infrastructure strength. Risk: oil price volatility; renewables capex returns being slower than expected; climate regulation.
8. Mercedes-Benz Group (MBG) Up 44%+
Mercedes is a German luxury automaker with strong brand equity and expanding EV offerings. The company's luxury positioning means it can charge premium prices for EVs. Operating margins are 12-15% (higher than competitors). The stock was beaten down in 2024-2025 over EV transition concerns, but recovery is underway. Valuation at 6-7x earnings is cheap for a luxury auto with pricing power. Risk: EV demand slowing; Chinese competition (BYD); supply chain disruptions.
9. Allianz SE (ALV) Up 38%+
Allianz is a German insurance and asset management giant. The company benefits from rising interest rates (insurance underwriting profitability), growing wealth management assets, and diversified geographic exposure. Valuation at 11-12x earnings is reasonable for a defensive, 5% grower. Dividend yield is 4.5%+ and sustainable. Risk: economic slowdown reducing insurance demand; investment portfolio volatility; geopolitical claims (e.g., war insurance).
10. Shell plc (SHEL) Up 41%+
Shell is a global oil and gas major with exposure to energy transition. The company has massive cash generation (40-50B annually) and is returning capital via buybacks and dividends. Dividend yield is 3.8%+ and growing. Energy transition investments are ramping. Valuation at 7-8x earnings reflects commodity exposure but also fortress balance sheet. Risk: oil price collapse; stranded asset risk if energy transition accelerates; climate regulation.
Why These Stocks Have Won
Industrial quality and diversification. European winners are not pure-play AI like US tech. They're quality industrial stocks (Siemens, ASML) with secular tailwinds (automation, semiconductors). This appeals to global institutional investors seeking diversification beyond mega-cap US tech. Pharma moats are durable. Novo Nordisk, Roche, and Europe's pharma sector have patent protection, regulatory moats, and pricing power. The GLP-1 wave has lifted all boats. Luxury has pricing power. LVMH and Mercedes benefit from wealthy consumers and brand equity. Luxury goods are less rate-sensitive than commodities or financial services. Energy transition is real capex. TotalEnergies and Shell are pivoting to renewables and still generating massive cash. Dividend yields (5-6%) are attractive to income investors. Valuations are cheaper than US. ASML at 35x is expensive, but Siemens at 22x or Mercedes at 6x are reasonably valued relative to US mega-caps trading at 40-60x.The Warning: European Growth Is Slower
European economies are growing 0-2% annually. This is better than recession, but far slower than the US (2-3%). European stocks reflect this reality: lower growth multiples, higher dividend yields, more cyclical exposure. Expect lower absolute returns than US tech.
Final Take: Quality and Diversification
1. ASML and SAP are European tech leaders. If you want European AI/tech exposure, these are the best-in-class.
2. Pharma and industrial provide quality. Novo Nordisk, Roche, Siemens offer defensibility and secular tailwinds.
3. Valuations are reasonable. Unlike US mega-caps, European stocks are not pricing in perfection. Risk-reward is balanced.
---
See the other side of European markets
Check out our analysis of the 10 worst-performing European stocks of 2026: legacy banks crumbling, telecom in freefall, legacy auto struggling, and energy dividend traps.
---
Disclaimer: This analysis is educational and not investment advice. Do your own research and consult a financial advisor before buying or selling. Track it live: ASML and compare with our Stock Screener.
